Dr. Robert Paine, Head of the Division of Lung Medicine at the University of Utah, and Dr. E. Scott Halstead, Associate Professor of Pediatrics at Penn State School of Medicine, are the study’s lead investigators. The iLeukPulm review is supported by the Executive Board of the Joint Programme of the U.S. Department of Defense (DoD) for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), under a $35 million contract for the complex progression and emergency use of Leucina for the treatment of Covid 19. The U.S. Food and Drug Administration (FDA) accepted the design of the exam. The study is recently recruiting patients at the University of Utah Health. Other sites are expected to register for the exam in the coming weeks.
Previous studies in patients with acute respiratory distress syndrome have shown that intravenous sargramostim is safe and related to a trend towards decreased mortality.1 These effects strongly help clinical studies evaluate the protection and efficacy of sargramostime in the remedy of COVID-19″ infection. Dr Paine said, adding, “I who administer sargramostim by inhalation as soon as patients are hospitalized and want oxygen because COVID-19 can simply improve recovery time, facilitate long-term lung recovery and decrease the need for invasive procedures like mechanical ventilation.”